stockportfolio.pro
Start 7-day free trial
Edwards Lifesciences Corporation (EW)
Healthcare · Medical Devices · NYSE
Edwards Lifesciences Corporation revenue & earnings (annual)
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $6.07B | $5.44B | $6.00B | $5.38B |
| Gross profit | $0 | $0 | $0 | $0 |
| Net income | $1.07B | $4.17B | $1.40B | $1.52B |
See the full financials for Edwards Lifesciences Corporation
Full income statement, balance sheet and cash flow (28+ line items across multiple years), an interactive price & market-cap chart, valuation ratios, and the ability to track EW in your own portfolio.
Start your 7-day free trialAbout Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.